SecBot SecBot
424B5 ·Filed Aug 4, 2026

TYRA

Tyra Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-333055
Notable filing: 424B5
Actionable Insight ▼ Bearish

The expanded ATM facility creates a persistent overhang; monitor daily volume and TD Cowen's selling activity for signs of accelerated distribution. With high short interest, any positive pipeline catalyst could trigger a squeeze, but the ATM cap increase suggests management expects to need more cash, likely capping near-term upside.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.71
T+0 close · Aug 4, 2026 · via day close
Latest settled
−17.37%
T+60 · $21.25
Vs SPY
−17.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $25.71entry
  2. T+1 · 3mo ago +4.86%α +5.02% · $26.96
  3. T+5 · 3mo ago −1.59%α −1.95% · $25.30
  4. T+20 · 3mo ago −2.26%α −1.65% · $25.13
  5. T+60 · 19d ago −17.37%α −17.56% · $21.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the maximum aggregate offering amount from $150 million to $250 million after fully utilizing the prior $150 million capacity. The filing signals ongoing dilution risk for existing shareholders as the company continues to access the public equity markets for capital, likely to fund its clinical-stage pipeline. With a $1.9B market cap and high short interest (~16.7%), the market may view this expanded ATM capacity as a near-term overhang on the stock.

Key Facts

  • Tyra Biosciences has fully utilized its prior $150 million ATM facility and amended the agreement to allow up to $250 million in total common stock sales.
  • The amendment was entered into on August 4, 2026, and the last reported sale price on August 3, 2026 was $32.04 per share.
  • The company is a clinical-stage biopharmaceutical firm with no disclosed revenue in this filing, relying on equity offerings for capital.
  • Short interest is approximately 16.7% of estimated shares outstanding as of mid-July 2026, indicating significant bearish positioning.

Financial Impact

Potential dilution of up to ~$100 million in additional common stock sales beyond the already-exhausted $150 million facility, representing roughly 5-8% of current market cap at the $32.04 reference price.

dilutionshare countmarket cap

Risk Factors

  • Continued dilution from ATM sales may pressure the stock price.
  • Clinical-stage biotech with no revenue; capital needs are uncertain and may require further equity raises.
  • High short interest could amplify downside if the ATM is used aggressively.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-333055
Document: 0001193125-26-333055-index-headers.html0001193125-26-333055
Document: 0001193125-26-333055-index.html0001193125-26-333055
Document: 0001193125-26-333055.txt0001193125-26-333055

Track record

13 reports on TYRA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
  2. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
  3. Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
  4. Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
  5. Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
  6. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
  7. Aug 4, 202614w ago 424B5 Bearish 6/10 Viewing Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
  9. May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
  10. Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026